Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoonROSE: GDC-4198 +/- Giredestrant vs Abemaciclib + Giredestrant in ER+/HER2- Breast Cancer
NCT07100106Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Oct 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of GDC-4198 in breast cancer (4 arms), sponsored by Genentech. Primary endpoints: Incidence and Severity of Adverse Events up to 36 months, Number of Participants With Dose-Limiting Toxicity and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
GDC-4198
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07100106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100106.